Business Description
Summit Therapeutics Inc
NAICS : 541714
SIC : 2833
ISIN : US86627T1088
Share Class Description:
SMMT: Ordinary SharesTotal Employee Number:
265Compare
Compare
Traded in other countries / regions
SMMT.USASMMT.Mexico Index Membership
Russell 1000Russell 3000Russell 2000Russell 2000 IPO Date
2015-03-05Description
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 29.88 | |||||
Equity-to-Asset | 0.84 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -0.02 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -56.3 | |||||
3-Year EPS without NRI Growth Rate | -10.1 | |||||
3-Year FCF Growth Rate | -25.7 | |||||
3-Year Book Growth Rate | 12.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 16.85 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 42.56 | |||||
9-Day RSI | 40.5 | |||||
14-Day RSI | 39.82 | |||||
3-1 Month Momentum % | -1.51 | |||||
6-1 Month Momentum % | -6.28 | |||||
12-1 Month Momentum % | -20.26 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 7.41 | |||||
Quick Ratio | 7.41 | |||||
Cash Ratio | 7.19 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -54.3 | |||||
Shareholder Yield % | 0.24 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -301.4 | |||||
ROA % | -254.6 | |||||
ROIC % | -3538.01 | |||||
3-Year ROIIC % | 407.31 | |||||
ROC (Joel Greenblatt) % | -9739.56 | |||||
ROCE % | -295.25 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 9 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 19.91 | |||||
Price-to-Tangible-Book | 20.03 | |||||
EV-to-EBIT | -8.5 | |||||
EV-to-EBITDA | -8.5 | |||||
EV-to-Forward-Revenue | 245.79 | |||||
EV-to-FCF | -26.79 | |||||
| Price-to-Net-Current-Asset-Value | 21.24 | |||||
| Price-to-Net-Cash | 21.91 | |||||
Earnings Yield (Greenblatt) % | -11.76 | |||||
FCF Yield % | -3.53 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SMMT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Summit Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.604 | ||
| Beta | 1.3187 | ||
| 3-Year Sharpe Ratio | 1.13 | ||
| 3-Year Sortino Ratio | 3.61 | ||
| Volatility % | 51.62 | ||
| 14-Day RSI | 39.82 | ||
| 14-Day ATR ($) | 0.944464 | ||
| 20-Day SMA ($) | 14.407 | ||
| 12-1 Month Momentum % | -20.26 | ||
| 52-Week Range ($) | 12.5501 - 30.98 | ||
| Shares Outstanding (Mil) | 776.16 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Summit Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Summit Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-20 08:00 | In 115 days | ||
| Third quarter earnings results for 2026 | 2026-10-20 | In 114 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-11 | In 44 days | ||
| Second quarter earnings results for 2026 | 2026-08-11 | In 44 days | ||
| General meeting for 2026 | 2026-06-10 08:30 | 14.29 (-1.24%) | ||
| 47th Annual Goldman Sachs Global Healthcare Conference | 2026-06-08 10:00 | 14.77 (-3.08%) | ||
| First quarter earnings conference call for 2026 | 2026-06-01 07:00 | 17.54 (-1.85%) | ||
| First quarter earnings results for 2026 | 2026-04-30 | 20.83 (-3.61%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-23 16:30 | 15.94 (+1.66%) | ||
| Annual report for 2025 | 2026-02-23 | 15.94 (+1.66%) |
Show
Entries
Summit Therapeutics Inc Frequently Asked Questions
What is Summit Therapeutics Inc(SMMT)'s stock price today?
The current price of SMMT is $14.02. The 52 week high of SMMT is $30.98 and 52 week low is $12.55.
When is next earnings date of Summit Therapeutics Inc(SMMT)?
The next earnings date of Summit Therapeutics Inc(SMMT) is 2026-08-11 Est..
Does Summit Therapeutics Inc(SMMT) pay dividends? If so, how much?
Summit Therapeutics Inc(SMMT) does not pay dividend.
Guru Commentaries on NAS:SMMT
No articles.
Press Release
Articles on Summit Therapeutics Inc
No articles.
Headlines
See More- 1
Jun 12, 2026
Summit rebounds after nearly $50M insider purchase
Seeking Alpha • 12:39pm
Jun 01, 2026
Summit falls despite phase 3 ivonescimab data in NSCLC
Seeking Alpha • 4:12pm
What's Going On With Summit Therapeutics Stock On Monday?
Benzinga • 9:56am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers